Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Quest Diagnostics

Related DGX
Addus HomeCare (PAL) Crumbles: Stock Drops 5.2% - Tale of the Tape
RadNet (RDNT) in Focus: Stock Adds 8.3% in Session - Tale of the Tape

In a report published Monday, Jefferies & Company reiterated its Hold rating on Quest Diagnostics (NYSE: DGX), but lowered its price target from $63.00 to $59.00.

Jefferies noted, “We continue to have a neutral view on DGX given our belief that ongoing weakness in lab volumes will persist and keep the stock rangebound near-term. While we are optimistic that mgmt's efforts to restructure operations and rationalize expenses will achieve their targets, we recognize that this process, which could be the key catalyst for the stock, will take time to complete.”

Quest Diagnostics closed on Friday at $57.94.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (DGX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free